Bisphosphonate therapy for unresectable symptomatic benign bone tumors: A long-term prospective study of tolerance and efficacy

Bone

Volumn 58, Issue , 2014, Pages 11-16

  Cornelis, F ^a   Truchetet, M E ^a   Amoretti, N ^b   Verdier, D ^a   Fournier, C ^a   Pillet, O ^c   Gille, O ^a   Hauger, O ^a  

^a HÔPITAL PELLEGRIN   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c Place Amélie Raba Léon   (France)

Author keywords

Bisphosphonate; Bone tumor; Tolerance

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ACETABULUM; ADOLESCENT; ADULT; ALTERNATIVE MEDICINE; ANEURYSMAL BONE CYST; ARTICLE; BONE NECROSIS; CERVICAL SPINE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEMUR SHAFT; FOLLOW UP; FRACTURE; GIANT CELL TUMOR; HUMAN; INFLAMMATION; INOPERABLE CANCER; LANGERHANS CELL HISTIOCYTOSIS; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; OSSIFICATION; OSTEOBLASTOMA; PAIN ASSESSMENT; PROSPECTIVE STUDY; SACRUM; SCHOOL CHILD; THORACIC SPINE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; VERTEBRA;

ABC; ANEURYSMAL BONE CYST; BISPHOSPHONATE; BONE TUMOR; BP; GCT; GIANT CELL TUMOR; LANGERHANS CELL HISTIOCYTOSIS; LCH; MDT; MULTIDISCIPLINARY MEETING; TOLERANCE;

ADOLESCENT; ADULT; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CHILD; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886003691     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.10.004     Document Type: Article

References (23)

1. Arzoo K., Sadeghi S., Pullarkat V. Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis. N Engl J Med 2001, 345:225-225.
2. Farran R.P., Zaretski E., Egeler R.M. Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol 2001, 23:54-56.
3. Montella L., Merola C., Merola G., Petillo L., Palmieri G. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab 2009, 27:110-113.
4. Kamizono J., Okada Y., Shirahata A., Tanaka Y. Bisphosphonate induces remission of refractory osteolysis in Langerhans cell histiocytosis. J Bone Miner Res 2002, 17:1926-1928.
5. Green J.R. Antitumor effects of bisphosphonates. Cancer 2003, 97:840-847.
6. Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002, 29:33-42.
7. Guise T.A. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008, 34(Suppl. 1):S19-S24.
8. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001, 7:377-387.
9. Neville-Webbe H.L., Holen I., Coleman R.E. The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002, 28:305-319.
10. Grauer A., Ziegler R. Bisphosphonate therapy in the management of skeletal metastases. Orthopade 1998, 27:231-239.
11. Cheng Y.Y., Huang L., Lee K.M., Xu J.K., Zheng M.H., Kumta S.M. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004, 75:71-77.
12. Gille O., Oliveira Bde A., Guerin P., Lepreux S., Richez C., Vital J.M. Regression of giant cell tumor of the cervical spine with bisphosphonate as single therapy. Spine (Phila Pa 1976) 2012, 37:E396-E399.
13. Chaudhary P., Khadim H., Gajra A., Damron T., Shah C. Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor. Onkologie 2011, 34:702-704.
14. Tse L.F., Wong K.C., Kumta S.M., Huang L., Chow T.C., Griffith J.F. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008, 42:68-73.
15. Sivendran S., Harvey H., Lipton A., Drabick J. Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series. Int J Hematol 2011, 93:782-786.
16. Weinstein R.S., Roberson P.K., Manolagas S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360:53-62.
17. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580-8587.
18. Fatterpekar G.M., Emmrich J.V., Eloy J.A., Aggarwal A. Bone-within-bone appearance: a red flag for bisphosphonate-associated osteonecrosis of the jaw. J Comput Assist Tomogr 2011, 35:553-556.
19. Bisdas S., Chambron Pinho N., Smolarz A., Sader R., Vogl T.J., Mack M.G. Bisphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 2008, 63:71-77.
20. Quattrocchi C.C., Santini D., Dell'aia P., Piciucchi S., Leoncini E., Vincenzi B., et al. A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid. Skeletal Radiol 2007, 36:1121-1127.
21. Kaban L.B., Troulis M.J., Wilkinson M.S., Ebb D., Dodson T.B. Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J Oral Maxillofac Surg 2007, 65:2018-2024. [discussion 2024].
22. Branstetter D.G., Nelson S.D., Manivel J.C., Blay J.Y., Chawla S., Thomas D.M., et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012, 18:4415-4424.
23. Lange T., Stehling C., Frohlich B., Klingenhofer M., Kunkel P., Schneppenheim R., et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J 2013 Jun, 22(6):1417-1422. Epub 2013 Mar 1. 10.1007/s00586-013-2715-7.